SCHEDULE: Vanguard Group Reports Zero Celldex Holdings Post-Realignment

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Celldex Therapeutics Inc. following an internal realignment.

Summary

• The Vanguard Group, Inc. filed an Amendment No. 3 to Schedule 13G regarding its beneficial ownership in Celldex Therapeutics Inc.
• As of the filing, The Vanguard Group reports 0% beneficial ownership of Celldex Therapeutics Inc. common stock, with zero sole or shared voting and dispositive power.
• This change is due to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions now report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated entities.
• The realignment and disaggregated reporting are in accordance with SEC Release No. 34-39538, dated January 12, 1998.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing. It reflects a change in reporting structure for The Vanguard Group, not a change in the underlying investment thesis for Celldex Therapeutics Inc. or a significant operational event.

Positives

• The Vanguard Group is adhering to SEC regulations by updating its beneficial ownership reporting following an internal realignment, demonstrating compliance.

Future Outlook

No forward-looking statements or guidance regarding Celldex Therapeutics Inc.'s performance or The Vanguard Group's future investment strategies are provided in this administrative filing.

Management Comments

• On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment.
• Certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release.
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.

Industry Context

StockSavvy.ai notes that such internal realignments and subsequent adjustments to beneficial ownership reporting are standard practice for large investment firms like The Vanguard Group, ensuring compliance with SEC regulations as their organizational structures evolve. This filing primarily reflects an administrative change in how Vanguard reports its holdings rather than a strategic shift in its investment in Celldex Therapeutics Inc.

Stakeholder Impact

• Shareholders (Celldex Therapeutics Inc.): No direct operational or financial impact on Celldex. The change is administrative for a major institutional investor's reporting.
• Shareholders (Vanguard Funds): The underlying investments held by Vanguard's funds remain unchanged; only the reporting entity for beneficial ownership has shifted internally.

Key Dates

Recommendation

This Schedule 13G amendment is purely administrative, reflecting an internal realignment within The Vanguard Group that changes how their beneficial ownership in Celldex Therapeutics Inc. is reported. It does not indicate a change in investment strategy, a divestment, or any new information regarding Celldex's operational or financial performance. Therefore, based solely on this filing, there is no new information to warrant a change from a 'hold' position for a seasoned investor, as the fundamental outlook for Celldex remains unaffected by this reporting adjustment.

Keywords

Celldex Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, SEC Filing, Investment Adviser, Common Stock, Ownership Change, Internal Realignment